Clinical Effect of Low Molecular Weight Heparin Calcium Combined with Rivaroxaban in the Treatment of Acute Pulmonary Thromboembolism
Objective:To investigate the clinical effect of Low Molecular Weight Heparin Calcium combined with Rivaroxaban in the treatment of acute pulmonary thromboembolism(APE),and to observe its influence on coagulation fibrinolysis and platelet activation.Method:A total of 100 patients with APE who treated in the Department of Respiratory and Critical Care Medicine of Shishi Hospital from January 2019 to January 2023 were selected as the study subjects,the patients were divided into the control group(Low Molecular Weight Heparin Calcium combined with Warfarin)and observation group(Low Molecular Weight Heparin Calcium combined with Rivaroxaban)by random number table method,50 cases in each group.The clinical efficacy,inflammatory factors[tumor necrosis factor-α(TNF-α),high-sensitivity C-reactive protein(hs-CRP),N-terminal pro-brain natriuretic peptide(NT-proBNP)],vascular endothelial function[soluble intercellular adhesion molecule 1(sICAM-1),endothelin 1(ET-1),thromboxane B2(TXB2)],coagulation and fibrinolysis indicators[protein C(PC),protein S(PS),D-dimer(D-D)],platelet activation indicators[platelet membrane glycoproteinⅡb/Ⅲa(GPⅡb/Ⅲa),P-selectin(P-selectin),angiotensinⅡ(AngⅡ),von Willebrand factor(vWF)]were compared between two groups.Result:The total effective rate of the control group was lower than that of the observation group,and the difference was statistically significant(P<0.05).There were no significant differences in the levels of inflammatory factors,vascular endothelial function,coagulation and fibrinolysis indicators and platelet activation indicators between two groups before treatment(P>0.05);the levels of TNF-α,hs-CRP,NT-proBNP,sICAM-1,ET-1,TXB2,PS,PC,D-D,GPⅡb/Ⅲa,P-selectin,AngⅡ and vWF in the observation group after treatment were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusion:Low Molecular Weight Heparin Calcium combined with Rivaroxaban in the treatment of APE can reduce inflammatory reaction,improve vascular endothelial and coagulation fibrinolytic function,and reduce the level of platelet activation factor,with remarkable effect.
万方数据
维普
